Head-to-head evidence
Lerodalcibep vs Ongericimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Lerodalcibep · Lerochol
Marketed by LIB Therapeutics
NCT04797104 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 478 patients that measured LDL-cholesterol lowering, the standard efficacy measure for this drug class. Lerodalcibep reduced LDL-C by more than half compared with placebo, a highly statistically significant result.
Next expected readout: July 2028 · NCT07102511 (registry estimate)
Ongericimab · Junshida
Developed by Shanghai Junshi Bioscience
NCT04781114 · Phase 3 · completed
This large, randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint was clearly met: both ongericimab dose regimens produced large, statistically significant reductions in LDL cholesterol versus placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lerodalcibep's landscape · Ongericimab's landscape